CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.48%197.801.2%$611.09m
GILDGilead Sciences, Inc.
0.28%68.200.9%$504.62m
CELGCelgene Corporation
-2.82%67.441.2%$479.41m
BIIBBiogen Inc.
0.65%321.281.3%$470.63m
ILMNIllumina, Inc.
0.44%302.923.5%$383.39m
REGNRegeneron Pharmaceuticals, Inc.
-0.28%338.052.6%$297.84m
VRTXVertex Pharmaceuticals Incorporated
-0.81%159.761.9%$258.42m
ALXNAlexion Pharmaceuticals, Inc.
1.68%116.992.0%$202.42m
AAgilent Technologies, Inc.
7.37%67.231.5%$199.71m
SRPTSarepta Therapeutics, Inc.
1.77%118.4215.4%$149.37m
LGNDLigand Pharmaceuticals Incorporated
1.68%151.0423.3%$141.92m
EXASExact Sciences Corporation
-2.42%65.6525.3%$133.70m
TSROTESARO, Inc.
13.90%41.9514.4%$124.60m
NKTRNektar Therapeutics
-0.03%38.005.6%$122.21m
INCYIncyte Corporation
-0.67%63.822.5%$114.96m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.